 LONDON WETHERBY, EnglandBUSINESS WIREAvacta Group plc AIM: AVCT, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumour biopsies obtained from six patients ... Avacta Announces Successful Completion of Fourth Dose Escala... 